urea has been researched along with Foot Dermatoses in 27 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "A parallel-group double-blind study was carried out which compared the efficacy of chemical avulsion of affected nail by urea 40% and bifonazole 1% cream alone with that of the same local therapy combined with short-term oral griseofulvin in onychomycosis." | 9.08 | Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. ( Bergman, R; Bitterman, O; Cohen, A; Friedman-Birnbaum, R; Shemer, A; Stettendorf, S, 1997) |
| "20 patients with distal onychomycosis were given daily application of an ointment containing 2% tolnaftate and an ointment containing 20% urea under ODT." | 9.05 | Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. ( Asai, Y; Hamada, T; Ishii, M, 1983) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 7.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "In the present study, we investigated the effects of bifonazole/urea ointment, a novel topical drug for the treatment of onychomycosis, on the ultrastructure of normal and fungus-infected human toenails by scanning electron microscopy." | 7.68 | Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment. ( Fritsch, H; Hegemann, L; Stettendorf, S, 1992) |
| "13 patients with distal subungual onychomycosis in a total of 48 dermatophyte-infected nails were treated with chemomechanical, partial nail avulsion followed by topical miconazole for 8 weeks." | 7.66 | Treatment of onychomycosis by partial nail avulsion and topical miconazole. ( Rollman, O, 1982) |
| " The number of patients with at least one adverse event was twice as high in the bifonazole-urea group in comparison to the 40% urea ointment with plastic dressing group." | 6.78 | Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized e ( Baran, R; Bulai-Livideanu, C; Coubetergues, H; Lahfa, M; Ortonne, JP; Paul, C; Piraccini, BM; Richert, B; Sibaud, V; Szepietowski, JC; Tosti, A; Voisard, JJ, 2013) |
| "Onychomycosis is difficult to cure as this requires eradication of the primary infection and protection of new areas of growth from reinfection." | 6.77 | Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. ( Emtestam, L; Kaaman, T; Rensfeldt, K, 2012) |
| "Onychomycosis is an increasingly common and recalcitrant fungal nail infection world-wide." | 6.69 | Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. ( Ahmad, SA; Ahmadpour, OA; Shamsi, S; Syed, TA, 1998) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "A parallel-group double-blind study was carried out which compared the efficacy of chemical avulsion of affected nail by urea 40% and bifonazole 1% cream alone with that of the same local therapy combined with short-term oral griseofulvin in onychomycosis." | 5.08 | Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. ( Bergman, R; Bitterman, O; Cohen, A; Friedman-Birnbaum, R; Shemer, A; Stettendorf, S, 1997) |
| "20 patients with distal onychomycosis were given daily application of an ointment containing 2% tolnaftate and an ointment containing 20% urea under ODT." | 5.05 | Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. ( Asai, Y; Hamada, T; Ishii, M, 1983) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 3.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "A new formulation was used as a nail lacquer containing 40% urea in a film-forming solution in 10 patients presenting with onychomycosis." | 3.71 | Chemical avulsion with urea nail lacquer. ( Baran, R; Tosti, A, 2002) |
| "In the present study, we investigated the effects of bifonazole/urea ointment, a novel topical drug for the treatment of onychomycosis, on the ultrastructure of normal and fungus-infected human toenails by scanning electron microscopy." | 3.68 | Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment. ( Fritsch, H; Hegemann, L; Stettendorf, S, 1992) |
| "13 patients with distal subungual onychomycosis in a total of 48 dermatophyte-infected nails were treated with chemomechanical, partial nail avulsion followed by topical miconazole for 8 weeks." | 3.66 | Treatment of onychomycosis by partial nail avulsion and topical miconazole. ( Rollman, O, 1982) |
| " The number of patients with at least one adverse event was twice as high in the bifonazole-urea group in comparison to the 40% urea ointment with plastic dressing group." | 2.78 | Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized e ( Baran, R; Bulai-Livideanu, C; Coubetergues, H; Lahfa, M; Ortonne, JP; Paul, C; Piraccini, BM; Richert, B; Sibaud, V; Szepietowski, JC; Tosti, A; Voisard, JJ, 2013) |
| "Onychomycosis is difficult to cure as this requires eradication of the primary infection and protection of new areas of growth from reinfection." | 2.77 | Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. ( Emtestam, L; Kaaman, T; Rensfeldt, K, 2012) |
| "Onychomycosis is an increasingly common and recalcitrant fungal nail infection world-wide." | 2.69 | Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. ( Ahmad, SA; Ahmadpour, OA; Shamsi, S; Syed, TA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (40.74) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joshipura, D | 1 |
| Goldminz, A | 1 |
| Greb, J | 1 |
| Gottlieb, A | 1 |
| Yao, Y | 1 |
| Mark, LA | 1 |
| Lahfa, M | 1 |
| Bulai-Livideanu, C | 1 |
| Baran, R | 2 |
| Ortonne, JP | 1 |
| Richert, B | 1 |
| Tosti, A | 2 |
| Piraccini, BM | 1 |
| Szepietowski, JC | 1 |
| Sibaud, V | 1 |
| Coubetergues, H | 1 |
| Voisard, JJ | 1 |
| Paul, C | 1 |
| Mayser, PA | 1 |
| Gries, A | 1 |
| Hamrouni, N | 1 |
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Emtestam, L | 1 |
| Kaaman, T | 1 |
| Rensfeldt, K | 1 |
| Federici, A | 1 |
| Federici, G | 1 |
| Milani, M | 1 |
| Torres-Rodríguez, JM | 1 |
| Sellart-Altisent, M | 1 |
| Rollman, O | 1 |
| Ishii, M | 1 |
| Hamada, T | 1 |
| Asai, Y | 1 |
| Woolf, WH | 1 |
| Schröder, W | 1 |
| Friedman-Birnbaum, R | 1 |
| Cohen, A | 1 |
| Shemer, A | 1 |
| Bitterman, O | 1 |
| Bergman, R | 1 |
| Stettendorf, S | 2 |
| Jennings, MB | 1 |
| Alfieri, D | 1 |
| Ward, K | 1 |
| Lesczczynski, C | 1 |
| Syed, TA | 1 |
| Ahmadpour, OA | 1 |
| Ahmad, SA | 1 |
| Shamsi, S | 1 |
| Ademola, J | 1 |
| Frazier, C | 1 |
| Kim, SJ | 1 |
| Theaux, C | 1 |
| Saudez, X | 1 |
| Pham, HT | 1 |
| Exelbert, L | 1 |
| Segal-Owens, AC | 1 |
| Veves, A | 1 |
| Fritsch, H | 1 |
| Hegemann, L | 1 |
| Nolting, S | 1 |
| Wang, DB | 1 |
| Yang, YT | 1 |
| Cao, RL | 1 |
| Cui, SY | 1 |
| Cao, ZR | 1 |
| Hay, RJ | 1 |
| Roberts, DT | 1 |
| Doherty, VR | 1 |
| Richardson, MD | 1 |
| Midgley, G | 1 |
| Wishnie, PA | 1 |
| Jenkin, W | 1 |
| Ruslanov, DV | 1 |
| Hindson, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes -a Randomized Controlled Trial[NCT02641548] | 120 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
12 trials available for urea and Foot Dermatoses
| Article | Year |
|---|---|
Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized e
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Female; Foot Dermatoses; Humans; Imidazoles | 2013 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Dru | 2012 |
An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controll
Topics: Administration, Topical; Adult; Aged; Arginine; Carnosine; Diabetes Mellitus, Type 2; Diabetic Foot; | 2012 |
Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; Foot Derma | 1983 |
Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Bl | 1997 |
Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; D | 1998 |
Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study.
Topics: Administration, Cutaneous; Adolescent; Adult; Antifungal Agents; Benzylamines; Dermatologic Agents; | 1998 |
Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedul | 2002 |
A prospective, randomized, controlled double-blind study of a moisturizer for xerosis of the feet in patients with diabetes.
Topics: Aged; Diabetic Foot; Double-Blind Method; Emollients; Female; Foot Dermatoses; Humans; Lactic Acid; | 2002 |
The topical treatment of onychomycosis using a new combined urea/imidazole preparation.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Clinical Trials as Topic; Drug Combinations | 1988 |
Carbamide in hyperkeratosis.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Eval | 1973 |
15 other studies available for urea and Foot Dermatoses
| Article | Year |
|---|---|
Acitretin for the treatment of recalcitrant plantar warts.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Adult; Foot Dermatoses; Foot Diseases; H | 2017 |
Woringer-Kolopp disease mimicking foot dermatitis.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; CD3 Complex; Dermatologic Agents; Diagnosis, Differential | 2012 |
[Trichophyton rubrum onychomycosis with secondary Aspergillus versicolor infection in a 12-year-old girl: successful topical therapy with terbinafine-urea ointment].
Topics: Administration, Topical; Antifungal Agents; Aspergillosis; Child; Drug Therapy, Combination; Female; | 2014 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Chemical avulsion with urea nail lacquer.
Topics: Administration, Cutaneous; Adult; Aged; Antifungal Agents; Cohort Studies; Female; Foot Dermatoses; | 2002 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug R | 2006 |
Treatment of onychomycosis by partial nail avulsion and topical miconazole.
Topics: Administration, Topical; Adult; Aged; Drug Therapy, Combination; Foot Dermatoses; Hand Dermatoses; H | 1982 |
Eradication of the problem plantar keratoma.
Topics: Administration, Topical; Adult; Aged; Female; Foot Dermatoses; Humans; Keratosis; Male; Middle Aged; | 1984 |
[Urea and its therapeutic possibilities].
Topics: Adult; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Scalp Dermatoses; Skin Diseases; | 1983 |
Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment.
Topics: Administration, Topical; Antifungal Agents; Drug Combinations; Foot Dermatoses; Humans; Imidazoles; | 1992 |
[Onychomycoses and their successful therapy].
Topics: Administration, Topical; Antifungal Agents; Drug Therapy, Combination; Foot Dermatoses; Hand Dermato | 1989 |
Urea plaster for softening diseased nails in the treatment of tinea unguium.
Topics: Foot Dermatoses; Hand Dermatoses; Humans; Ointments; Onychomycosis; Urea | 1986 |
Uses of urea in podiatric medicine.
Topics: Foot Dermatoses; Humans; Nail Diseases; Toes; Urea | 1987 |
[Basis and comparative evaluation of the combined therapy of patients with foot and hand mycoses].
Topics: Antibody Formation; Dermatomycoses; Dimethyl Sulfoxide; Drug Therapy, Combination; Foot Dermatoses; | 1985 |
Urea in the topical treatment of atopic eczema.
Topics: Adult; Betamethasone; Child; Child, Preschool; Chronic Disease; Dermatologic Agents; Eczema; Foot De | 1971 |